Trevena, Inc. (TRVN): History, Ownership, Mission, How It Works & Makes Money

Ever heard of Trevena, Inc. (TRVN), and wondered what they're all about? This biopharmaceutical company is focused on developing and commercializing medicines for central nervous system (CNS) disorders. With their innovative approach and a pipeline including one FDA-approved product, Olinvyk, Trevena is striving to address critical needs in the CNS space, but how exactly do they operate and generate revenue, especially given their recent delisting from Nasdaq in October 2024 and transition to the Pink Open Market?

Trevena, Inc. (TRVN) History

Trevena, Inc.'s Founding Timeline

Year established

Trevena, Inc. was established in 2007.

Original location

The company was originally located in King of Prussia, Pennsylvania.

Founding team members

The founding team members include:

• Robert Lefkowitz, M.D.
• Howard Rockman, M.D.
• Jonathan Violin, Ph.D.

Initial capital/funding

Trevena, Inc. secured an initial Series A financing of $23 million in 2007, led by Alta Partners and New Enterprise Associates.

Trevena, Inc.'s Evolution Milestones

Trevena, Inc.'s Transformative Moments

• FDA Approval of Olinvyk: The FDA approval of Olinvyk in August 2020 was a pivotal moment. It marked the transition from a clinical-stage company to a commercial entity.
• Focus on G Protein-Coupled Receptors (GPCRs): Trevena's specialization in GPCR-targeted drug development has been a consistent theme, shaping its research and development efforts.
• Partnerships and Collaborations: Strategic collaborations to expand the reach of Olinvyk and explore new therapeutic opportunities have influenced its growth.

To gain more insights into the company's financial standing, read this comprehensive analysis: Breaking Down Trevena, Inc. (TRVN) Financial Health: Key Insights for Investors

Trevena, Inc. (TRVN) Ownership Structure

Understanding the ownership structure of Trevena, Inc. (TRVN) provides insights into who controls the company and whose interests may be prioritized. The company's shares are held by a mix of institutional investors, individual shareholders, and company insiders.

Trevena, Inc.'s Current Status

Trevena, Inc. is a public company, meaning its shares are traded on a stock exchange, allowing anyone to buy and sell them. As a publicly traded entity, it is subject to regulations and reporting requirements.

Trevena, Inc.'s Ownership Breakdown

The ownership of Trevena, Inc. is distributed among various shareholders, with institutional investors holding a significant portion. The following table summarizes the ownership breakdown:

Trevena, Inc.'s Leadership

As of April 2025, Trevena, Inc.'s leadership team comprises experienced individuals who guide the company's strategic direction. Key members include:

• Carrie L. Bourdow: President and Chief Executive Officer
• Barry J. Alperin, M.D.: Executive Vice President, Chief Medical Officer
• Christine L. Dorfler: Senior Vice President, Chief Financial Officer

For more insights into the financial health of the company, check out: Breaking Down Trevena, Inc. (TRVN) Financial Health: Key Insights for Investors

Trevena, Inc. (TRVN) Mission and Values

Trevena, Inc. focuses on discovering, developing, and commercializing innovative therapies for patients with central nervous system (CNS) disorders. Their mission reflects a commitment to addressing unmet medical needs through scientific advancements and a patient-centric approach.

Trevena, Inc.'s Core Purpose

Official mission statement

Trevena's mission statement is to drive innovation in the treatment of central nervous system (CNS) disorders, with a focus on acute care settings. This involves:

• Developing and commercializing novel therapies that can improve patient outcomes.
• Addressing significant unmet medical needs in pain management and other CNS conditions.
• Leveraging their expertise in G protein-biased ligand drug discovery to create differentiated products.

Vision statement

While a specific formal vision statement may not be explicitly publicized, Trevena's actions and strategic goals suggest a vision centered on:

• Becoming a leader in the development of innovative CNS therapeutics.
• Establishing a portfolio of differentiated products that offer clinical advantages over existing treatments.
• Expanding their pipeline through internal research and strategic collaborations.

Company slogan/tagline

Trevena does not have a widely publicized official slogan or tagline. However, considering their focus and mission, potential taglines that align with their objectives could be:

• 'Innovating CNS Therapies for a Better Future.'
• 'Advancing Pain Management Through Science.'
• 'Transforming CNS Care, One Innovation at a Time.'

To delve deeper into Trevena's mission, vision, and core values, explore: Mission Statement, Vision, & Core Values of Trevena, Inc. (TRVN).

Trevena, Inc. (TRVN) How It Works

Trevena, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel and differentiated therapies for the central nervous system (CNS). They aim to address unmet medical needs by targeting validated receptors with innovative approaches.

Trevena, Inc.'s Product/Service Portfolio

Trevena, Inc.'s Operational Framework

Trevena operates through a focused research and development strategy, clinical trials, and commercial partnerships to bring its products to market. Key aspects of their operational framework include:

• Drug Discovery and Development: Trevena utilizes its expertise in G protein-biased ligands to discover and develop new chemical entities that target specific receptors in the CNS.
• Clinical Trials: The company conducts rigorous clinical trials to evaluate the safety and efficacy of its drug candidates. These trials are essential for regulatory approval and market access.
• Regulatory Approval: Trevena works closely with regulatory agencies like the FDA to secure approval for its products. This involves submitting comprehensive data packages that demonstrate the safety and efficacy of their drugs.
• Commercialization: Trevena commercializes its products through a combination of its own sales force and strategic partnerships. For example, they have collaborated with companies like Viatris for the commercialization of OLINVYK.
• Manufacturing: They rely on third-party manufacturers to produce their products.

Trevena, Inc.'s Strategic Advantages

Trevena's strategic advantages stem from its innovative approach to drug development and its focus on addressing unmet medical needs:

• Novel Technology Platform: Trevena's G protein-biased ligand platform allows them to design drugs that selectively activate specific signaling pathways, potentially leading to improved therapeutic outcomes and reduced side effects.
• Targeted Therapies: By focusing on specific receptors and pathways involved in pain and CNS disorders, Trevena can develop therapies that are more effective and have fewer off-target effects.
• Strategic Partnerships: Collaborations with other pharmaceutical companies and research institutions provide Trevena with access to additional resources, expertise, and market reach.
• Addressing Unmet Needs: Trevena focuses on developing therapies for conditions where there are limited treatment options or significant unmet needs, such as acute pain and CNS disorders.

For more insights into the company's financial standing, consider reading: Breaking Down Trevena, Inc. (TRVN) Financial Health: Key Insights for Investors

Trevena, Inc. (TRVN) How It Makes Money

Trevena, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of novel pain management therapies. The company primarily generates revenue through the sale of its approved products, particularly OLINVYK (oliceridine), and through potential partnerships, licensing agreements, and collaborations with other pharmaceutical companies.

Trevena, Inc.'s Revenue Breakdown

As of April 2025, the revenue breakdown for Trevena, Inc. can be described based on available information regarding their product and financial activities. Please note that exact percentages may vary and are subject to change based on the company's financial reports.

Trevena, Inc.'s Business Economics

Trevena's business economics are influenced by several key factors:

• Pricing Strategy: The pricing of OLINVYK is crucial. It needs to be competitive within the market for IV analgesics while also reflecting the value proposition of its unique mechanism of action and potential benefits, such as a potentially improved safety profile compared to traditional opioids.
• Market Access: Securing formulary access and favorable reimbursement rates from healthcare providers and insurance companies is essential for driving sales. Negotiations and agreements with these entities can significantly impact revenue.
• Cost Management: Efficient management of research and development expenses, as well as sales and marketing costs, is vital for maintaining profitability. Strategic decisions regarding outsourcing and partnerships can help control costs.
• Intellectual Property: The strength and duration of patent protection for OLINVYK and other pipeline products are critical for maintaining market exclusivity and defending against competition.

Trevena, Inc.'s Financial Performance

Trevena's financial performance can be assessed through the following points:

• Revenue Growth: The growth in sales of OLINVYK is a key indicator. Monitoring quarterly and annual revenue trends provides insights into the product's market acceptance and commercial success.
• Operating Expenses: Analyzing operating expenses, including R&D and SG&A, helps assess the company's efficiency in managing its resources. Significant fluctuations in these expenses can signal changes in strategy or financial health.
• Cash Position: Monitoring the company's cash reserves and burn rate is crucial, especially for a biopharmaceutical company that requires substantial investment in R&D. A strong cash position provides financial flexibility and runway for continued operations.
• Profitability: While many biopharmaceutical companies may not be immediately profitable, tracking progress towards profitability is important. Key metrics include gross margin, operating margin, and net income.
• Partnership and Collaboration: Revenue from partnerships and collaborations can provide significant financial boosts. The terms and success of these agreements impact overall financial stability.

To gain a deeper understanding of Trevena, Inc.'s financial health, consider exploring this resource: Breaking Down Trevena, Inc. (TRVN) Financial Health: Key Insights for Investors

Trevena, Inc. (TRVN) Market Position & Future Outlook

Trevena Inc. is navigating a challenging pharmaceutical landscape, striving to solidify its market presence with a focus on novel pain management therapies. To gain more insight into the investors influencing Trevena's trajectory, check out: Exploring Trevena, Inc. (TRVN) Investor Profile: Who’s Buying and Why?

Competitive Landscape

Opportunities & Challenges

Industry Position

Trevena, Inc. holds a unique position within the pharmaceutical industry, particularly in the acute pain management sector. Here's how they stand:

• Niche Player: Trevena operates as a niche player, focusing on addressing unmet needs in acute pain management with innovative solutions like Olinvyk.
• Innovation Focus: The company differentiates itself through its focus on novel drug development and differentiated mechanisms of action.
• Partnerships: Strategic collaborations and partnerships are vital for expanding market reach and accelerating commercialization efforts.